Incyte Corporation – NASDAQ:INCY
Incyte stock price today
$85.46
+16.22
+23.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Incyte stock price monthly change
+8.75%
month
Incyte stock price quarterly change
+8.75%
quarter
Incyte stock price yearly change
+10.45%
year
Incyte key metrics
Market Cap | 13.21B |
Enterprise value | 13.43B |
P/E | 47.54 |
EV/Sales | 3.95 |
EV/EBITDA | 22.39 |
Price/Sales | 4.81 |
Price/Book | 3.74 |
PEG ratio | -0.74 |
EPS | 3.33 |
Revenue | 3.76B |
EBITDA | 958.42M |
Income | 745.44M |
Revenue Q/Q | 8.93% |
Revenue Y/Y | 8.58% |
Profit margin | 10.04% |
Oper. margin | 17.07% |
Gross margin | 93.9% |
EBIT margin | 17.07% |
EBITDA margin | 25.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIncyte stock price history
Incyte stock forecast
Incyte financial statements
Average Price Target
$92.3
Potential upside: 8.00%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 954.61M | 203.54M | 21.32% |
|---|---|---|---|
| Sep 2023 | 919.02M | 171.26M | 18.64% |
| Dec 2023 | 1.01B | 201.07M | 19.84% |
| Mar 2024 | 880.88M | 169.54M | 19.25% |
| Jun 2023 | 6208259000 | 1.46B | 23.64% |
|---|---|---|---|
| Sep 2023 | 6388239000 | 1.45B | 22.8% |
| Dec 2023 | 6782107000 | 1.59B | 23.48% |
| Mar 2024 | 7135605000 | 1.74B | 24.4% |
| Jun 2023 | 306.52M | -7.42M | 12.86M |
|---|---|---|---|
| Sep 2023 | 147.83M | -17.18M | -37.25M |
| Dec 2023 | 147.72M | -154.5M | 346K |
| Mar 2024 | 218.81M | -73.11M | -12.41M |
Incyte alternative data
Incyte Products
| 19 Feb 2023 | 6 | 1 | 1 | 9 | 0 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 6 | 0 | 2 | 14 | 0 |
| 5 Mar 2023 | 5 | 0 | 1 | 11 | 1 |
| 12 Mar 2023 | 5 | 0 | 0 | 11 | 0 |
| 19 Mar 2023 | 6 | 0 | 1 | 12 | 1 |
| 26 Mar 2023 | 5 | 1 | 1 | 12 | 0 |
| 2 Apr 2023 | 4 | 1 | 2 | 12 | 2 |
| 9 Apr 2023 | 6 | 2 | 2 | 13 | 1 |
| 16 Apr 2023 | 6 | 1 | 2 | 7 | 0 |
| 23 Apr 2023 | 6 | 0 | 1 | 11 | 0 |
| 30 Apr 2023 | 5 | 1 | 1 | 13 | 0 |
| 7 May 2023 | 7 | 0 | 2 | 11 | 1 |
| 14 May 2023 | 5 | 2 | 0 | 12 | 0 |
| 21 May 2023 | 5 | 0 | 1 | 10 | 1 |
| 28 May 2023 | 4 | 0 | 1 | 13 | 0 |
| 4 Jun 2023 | 7 | 2 | 2 | 10 | 0 |
| 11 Jun 2023 | 6 | 0 | 1 | 12 | 1 |
| 18 Jun 2023 | 5 | 0 | 1 | 9 | 1 |
| 25 Jun 2023 | 5 | 0 | 0 | 11 | 2 |
| 2 Jul 2023 | 4 | 1 | 2 | 11 | 0 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 52 |
|---|---|
| Sep 2023 | 61 |
| Oct 2023 | 62 |
| Nov 2023 | 48 |
| Dec 2023 | 42 |
| Jan 2024 | 47 |
| Feb 2024 | 49 |
| Apr 2024 | 71 |
| May 2024 | 78 |
| Jun 2024 | 83 |
| Jul 2024 | 64 |
| Dec 2024 | 70 |
| Jan 2025 | 76 |
| Feb 2025 | 111 |
| May 2025 | 119 |
| Jul 2025 | 116 |
| Aug 2025 | 101 |
| Aug 2023 | 2,324 |
|---|---|
| Sep 2023 | 2,324 |
| Oct 2023 | 2,324 |
| Nov 2023 | 2,324 |
| Dec 2023 | 2,324 |
| Jan 2024 | 2,324 |
| Feb 2024 | 2,324 |
| Mar 2024 | 2,524 |
| Apr 2024 | 2,524 |
| May 2024 | 2,524 |
| Jun 2024 | 2,524 |
| Jul 2024 | 2,524 |
Incyte other data
91.83%
+0.80%
of INCY is owned by hedge funds
505
-6
203.92M
+1.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 8022 |
| Jun 2024 | 0 | 20257 |
| Jul 2024 | 0 | 25025 |
| Aug 2024 | 0 | 11608 |
| Sep 2024 | 0 | 9404 |
| Nov 2024 | 0 | 9723 |
| Dec 2024 | 0 | 1300 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | TRAY THOMAS officer: Principal Accounting O.. | Common Stock | 650 | $69.31 | $45,052 | ||
Sale | TRAY THOMAS officer: Principal Accounting O.. | Common Stock | 650 | $70.64 | $45,916 | ||
Sale | IYENGAR VIJAY K officer: EVP, GMA.. | Common Stock | 360 | $75.6 | $27,216 | ||
Sale | IYENGAR VIJAY K officer: EVP, GMA.. | Common Stock | 5,683 | $75.37 | $428,328 | ||
Option | FLANNELLY BARRY P officer: EVP & General Manager US | Common Stock | 2,256 | $68.62 | $154,807 | ||
Sale | FLANNELLY BARRY P officer: EVP & General Manager US | Common Stock | 1,424 | $82 | $116,768 | ||
Option | FLANNELLY BARRY P officer: EVP & General Manager US | Common Stock | 1,424 | $72.27 | $102,912 | ||
Sale | FLANNELLY BARRY P officer: EVP & General Manager US | Common Stock | 2,256 | $78.21 | $176,442 | ||
Option | FLANNELLY BARRY P officer: EVP & General Manager US | Employee Stock Option (right to buy) | 3,680 | $70.45 | $259,238 | ||
Sale | TRAY THOMAS officer: Principal Accounting O.. | Common Stock | 382 | $63.37 | $24,207 |
| Patent |
|---|
Application Filling date: 28 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 24 Feb 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 19 Dec 2019 Issue date: 30 Aug 2022 |
Application Filling date: 23 Feb 2021 Issue date: 11 Aug 2022 |
Application Filling date: 30 Nov 2021 Issue date: 4 Aug 2022 |
Application Filling date: 29 Dec 2021 Issue date: 28 Jul 2022 |
Application Filling date: 10 Jan 2022 Issue date: 21 Jul 2022 |
Application Filling date: 2 Dec 2021 Issue date: 7 Jul 2022 |
Application Filling date: 3 Dec 2021 Issue date: 30 Jun 2022 |
Application Filling date: 3 Dec 2021 Issue date: 16 Jun 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Herve Hoppenot (1960) Chairman, Pres & Chief Executive Officer | $2,550,000 |
| Ms. Christiana Stamoulis (1971) Executive Vice President & Chief Financial Officer | $989,390 |
| Dr. Steven H. Stein (1967) Executive Vice President & Chief Medical Officer | $967,800 |
| Dr. Vijay K. Iyengar M.D. (1973) Executive Vice President of Global Strategy & Corporation Devel. | $945,900 |
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA (1958) Executive Vice President & GM of North America | $833,630 |
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs
I Scanned The S&P 500 For GARP Stocks; Here's What I Found
Top 4 Immunology Stocks Poised For Growth In 2025
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Incyte: Multiple Drug Launches Bode Well For Future Growth
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Incyte: The Worst Has Been Avoided
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
-
What's the price of Incyte stock today?
One share of Incyte stock can currently be purchased for approximately $85.46.
-
When is Incyte's next earnings date?
Unfortunately, Incyte's (INCY) next earnings date is currently unknown.
-
Does Incyte pay dividends?
No, Incyte does not pay dividends.
-
How much money does Incyte make?
Incyte has a market capitalization of 13.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.87% to 3.7B US dollars.
-
What is Incyte's stock symbol?
Incyte Corporation is traded on the NASDAQ under the ticker symbol "INCY".
-
What is Incyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Incyte?
Shares of Incyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Incyte's key executives?
Incyte's management team includes the following people:
- Mr. Herve Hoppenot Chairman, Pres & Chief Executive Officer(age: 65, pay: $2,550,000)
- Ms. Christiana Stamoulis Executive Vice President & Chief Financial Officer(age: 54, pay: $989,390)
- Dr. Steven H. Stein Executive Vice President & Chief Medical Officer(age: 58, pay: $967,800)
- Dr. Vijay K. Iyengar M.D. Executive Vice President of Global Strategy & Corporation Devel.(age: 52, pay: $945,900)
- Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA Executive Vice President & GM of North America(age: 67, pay: $833,630)
-
How many employees does Incyte have?
As Jul 2024, Incyte employs 2,524 workers.
-
When Incyte went public?
Incyte Corporation is publicly traded company for more then 31 years since IPO on 4 Nov 1993.
-
What is Incyte's official website?
The official website for Incyte is incyte.com.
-
Where are Incyte's headquarters?
Incyte is headquartered at 1801 Augustine Cut-Off, Wilmington, DE.
-
How can i contact Incyte?
Incyte's mailing address is 1801 Augustine Cut-Off, Wilmington, DE and company can be reached via phone at +30 24986700.
-
What is Incyte stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Incyte in the last 12 months, the avarage price target is $92.3. The average price target represents a 8.00% change from the last price of $85.46.
Incyte company profile:
Incyte Corporation
incyte.comExchange:
NASDAQ
Full time employees:
2,524
Industry:
Biotechnology
Sector:
Healthcare
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
1801 Augustine Cut-Off
Wilmington, DE 19803
Wilmington, DE 19803
CIK: 0000879169
ISIN: US45337C1027
CUSIP: 45337C102
